Oppenheimer Concludes Third Annual Immuno-Oncology Education Event At MD Anderson Cancer Center In Houston August 18-19

HOUSTON, Aug. 20, 2015 /PRNewswire/ -- Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings (NYSE: OPY), hosted its Third Annual Immuno-Oncology Education Event at The University of Texas MD Anderson Cancer Center and the Four Seasons Hotel in Houston on August 18, 2015. The two-day event featured presentations from the foremost research scientists in immuno-oncology and one-on-one meetings with leading public and private companies in the immuno-oncology space.

Now in its third year, the MD Anderson event anchors Oppenheimer's "On-site Insights Series," which is designed to educate investors on current developments in oncology research. MD Anderson, the nation's No. 1 hospital for cancer care, also is committed to educating its students, patients, employees and the public about cancer.

"As a leader in biotechnology and life sciences equity research, we are pleased to partner with MD Anderson to offer our clients access to prominent scientists, allowing them to better understand new developments in cancer treatments and to better inform their investment decisions," said Erica L. Moffett, Managing Director and Associate Director of Research at Oppenheimer.

Companies participating in the event included: Affimed N.V.; Agenus Inc.; arGen-X; Armo Biosciences; Cellectis; Kite Pharma; MacroGenics, Inc.; Pieris Pharmaceuticals, Inc.; Trillium Therapeutics Inc.; Xencor, Inc.; and Zymeworks.

"Conquering cancer requires the collective effort of academia, government and the private sector," said Ronald A. DePinho, M.D., president, MD Anderson. "To fulfill our mission to end cancer, we must convert our discoveries into lifesaving drugs through robust collaborations. We're pleased to educate Oppenheimer's team and their colleagues on the extraordinary advances in cancer."

In addition to Dr. DePinho, the event also featured the following MD Anderson scientists: Jim Allison, Ph.D.; Laurence Cooper, M.D., Ph.D.; Nathan Fowler, M.D.; Jeffrey Molldrem, M.D.; and Katy Rezvani, M.D., Ph.D.

Oppenheimer Research Analysts at the event included:

• Wendy Lam, Ph.D., Senior Analyst, Biotechnology
• Christopher Marai Ph.D., Senior Analyst, Biotechnology
• Ling Wang, CFA, Senior Analyst, Biotechnology
• Akiva Felt, Senior Analyst, Bio & Specialty Pharmaceuticals

Other events for Oppenheimer's "On-site Insights Series" occur throughout the year at leading university research institutions across the country. The next event in the series will be held in the fall at the Albert Einstein College of Medicine in New York City.

Oppenheimer's next conference is its 26th Annual Healthcare Conference December 8-9 in New York City. These meetings provide additional opportunities for institutional investors as well as venture capital and private equity firms to meet with a variety of companies.

Conferences are open only to established institutional clients of Oppenheimer & Co. Inc. For more information, please contact your Oppenheimer & Co. Inc. institutional sales representative.

Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Certain statements in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oppenheimer-concludes-third-annual-immuno-oncology-education-event-at-md-anderson-cancer-center-in-houston-august-18-19-300131485.html

SOURCE Oppenheimer & Co. Inc.